143 related articles for article (PubMed ID: 19002391)
1. Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China.
Bai J; Xue Y; Ye L; Yao J; Zhou C; Shao Z; Qian L; Yang R; Li H; Zhang H; Zheng Y
Int J Hematol; 2008 Dec; 88(5):530-535. PubMed ID: 19002391
[TBL] [Abstract][Full Text] [Related]
2. [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].
Bai J; Xue YP; Ye L; Yao JF; Zhou CL; Qian LS; Yang RC; Li HY; Zhang HY; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):685-8. PubMed ID: 18399175
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
[TBL] [Abstract][Full Text] [Related]
4. [Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center].
Bai J; Shi H; Ai L; Zhang L; Zhou Y; Li Z; Zhao Y; Sheng M; Li D; Li H; Qian L; Mi Y; Xiao Z; Zheng Y; Yang R; Xue Y
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1364-8. PubMed ID: 26178350
[TBL] [Abstract][Full Text] [Related]
5. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.
Passamonti F; Rumi E; Caramella M; Elena C; Arcaini L; Boveri E; Del Curto C; Pietra D; Vanelli L; Bernasconi P; Pascutto C; Cazzola M; Morra E; Lazzarino M
Blood; 2008 Apr; 111(7):3383-7. PubMed ID: 18187660
[TBL] [Abstract][Full Text] [Related]
6. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic myeloid metaplasia. Its evolution into acute leukemia.
Silverstein MN; Brown AL; Linman JW
Arch Intern Med; 1973 Nov; 132(5):709-12. PubMed ID: 4518465
[No Abstract] [Full Text] [Related]
9. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs.
Crisà E; Venturino E; Passera R; Prina M; Schinco P; Borchiellini A; Giai V; Ciocca Vasino MA; Bazzan M; Vaccarino A; Boccadoro M; Ferrero D
Ann Hematol; 2010 Jul; 89(7):691-9. PubMed ID: 20146064
[TBL] [Abstract][Full Text] [Related]
10. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
11. Thrombosis in patients with post-polycythemia vera myelofibrosis: incidence and risk factors.
Teng G; Zhou Y; Zhang Y; Hu N; Liu T; Han Y; Gao C; Zhang L; Bai J
Thromb Res; 2022 Apr; 212():38-43. PubMed ID: 35219930
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Kiladjian JJ; Gardin C; Renoux M; Bruno F; Bernard JF
Hematol J; 2003; 4(3):198-207. PubMed ID: 12764352
[TBL] [Abstract][Full Text] [Related]
13. The haematocrit and platelet target in polycythemia vera.
Di Nisio M; Barbui T; Di Gennaro L; Borrelli G; Finazzi G; Landolfi R; Leone G; Marfisi R; Porreca E; Ruggeri M; Rutjes AW; Tognoni G; Vannucchi AM; Marchioli R;
Br J Haematol; 2007 Jan; 136(2):249-59. PubMed ID: 17156406
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
[TBL] [Abstract][Full Text] [Related]
15. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
Ronner L; Podoltsev N; Gotlib J; Heaney ML; Kuykendall AT; O'Connell C; Shammo J; Fleischman AG; Scherber RM; Mesa R; Yacoub A; Perkins C; Meckstroth S; Behlman L; Chiaramonte M; Salehi M; Ziadkhanpour K; Nguyen H; Siwoski O; Hung AK; Janania Martinez M; Nguyen J; Patel S; Kollipara R; Dave A; Randall M; Grant M; Harrison M; Fernandez Soto P; Tremblay D; Hoffman R; Moshier E; Mascarenhas J
Blood; 2020 May; 135(19):1696-1703. PubMed ID: 32107559
[TBL] [Abstract][Full Text] [Related]
16. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
Kamiunten A; Shide K; Kameda T; Sekine M; Kubuki Y; Ito M; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Akizuki K; Tahira Y; Shimoda H; Hidaka T; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Jun; 107(6):681-688. PubMed ID: 29488167
[TBL] [Abstract][Full Text] [Related]
17. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Passamonti F; Lazzarino M
Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
[TBL] [Abstract][Full Text] [Related]
18. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
19. Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
Habberstad AH; Tran HTT; Randen U; Spetalen S; Dybedal I; Tjønnfjord GE; Dahm AEA
J Med Case Rep; 2018 Apr; 12(1):105. PubMed ID: 29685167
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
